Medical devices, healthcare technology and the business of care
PMA approval · P180014

XPS with Steen Solution Perfusate

Xvivo Perfusion, Inc. · Decision date Apr 26, 2019

MEDTECHLEDGER EXPLANATIONP180014

What did the FDA approve?

FDA approved the XPS with Steen Solution Perfusate on April 26, 2019, under PMA number P180014. The approval statement describes the device as intended for flushing and temporary continuous normothermic machine perfusion of initially unacceptable excised donor lungs, during which ex vivo function can be reassessed for transplantation.

The applicant is Xvivo Perfusion, Inc., and the device category is a normothermic preservation system for transplantation of initially unacceptable donor lungs. The statement reports the intended use but does not itself provide independent proof of safety or clinical effectiveness. No supplement type or supplement reason is listed, and the source does not describe a relationship to any earlier PMA.

FDA approval order statement

Approval for the XPS with Steen Solution Perfusate. This device is indicated for use in flushing and temporary continuous normothermic machine perfusion of initially unacceptable excised donor lungs during which time the ex vivo function of the lungs can be reassessed for transplantation.
Regulatory pathway
Original PMA
Clinical specialty
Gastroenterology, Urology
Decision date
Apr 26, 2019

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
P180014
Regulatory pathway
Premarket approval application
Product code
PHO
Decision code
APPR
Decision date
Apr 26, 2019
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Normothermic preservation system for transplantation of initially unacceptable donor lungs.

Product code
PHO
FDA device class
3

The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.

FDA decision timeline

  1. P180014 received

    Application receipt date recorded by FDA.

  2. P180014 · FDA decision

    APPR

  3. P180014/S014 · Related supplement

    XPS with Steen Solution Perfusate

Timeline entries are records held by MedtechLedger for P180014. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P180014

Product / regulatory recordCompanyPathwayDecision dateSource
Xvivo Perfusion, Inc.PMA supplementSep 16, 2026FDA

Explore the linked device profile

Other records with product code PHO

Product / regulatory recordCompanyPathwayDecision dateSource
Traferox Technologies, Inc.PMA supplementOct 30, 2026FDA
Traferox Technologies, Inc.PMA supplementOct 30, 2026FDA
LungFX DeviceP240033/S001
Lung Bioengineering, Inc.PMA supplementOct 16, 2026FDA
LungFX DeviceP240033/S002
Lung Bioengineering, Inc.PMA supplementOct 16, 2026FDA
Traferox Technologies, Inc.PMA approvalJul 15, 2026FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Xvivo Perfusion, Inc.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
3666 S Inca St., Englewood, CO, 80110

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records